|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Aura Biosciences, Inc. (AURA) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
49,210,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aura Biosciences is a clinical-stage biotechnology company using its targeted oncology platform to develop a potential new standard of care across various cancer indications, with an initial focus on ocular and urologic oncology. Co.'s proprietary platform enables the targeting of a range of solid tumors using Virus-Like Particles that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates (VDC). AU-011, Co.'s VDC candidate, is being developed for the first line treatment of primary choroidal melanoma. In addition, Co. is developing AU-011 for the treatment of non-muscle invasive bladder cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,779,667 |
3,045,667 |
| Total Buy Value |
$0 |
$0 |
$15,643,162 |
$30,826,673 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
7 |
12 |
| Total Shares Sold |
0 |
22,462 |
46,782 |
57,290 |
| Total Sell Value |
$0 |
$171,662 |
$396,896 |
$527,771 |
| Total People Sold |
0 |
2 |
2 |
4 |
| Total Sell Transactions |
0 |
2 |
6 |
10 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Johnson David Michael |
Director |
– • – |
2023-01-05 |
4 |
B |
$10.00 |
$3,960 |
I/I |
396 |
17,096 |
2.1 |
- |
|
| Johnson David Michael |
Director |
– • – |
2022-12-28 |
4 |
B |
$9.75 |
$39,000 |
I/I |
4,000 |
17,000 |
2.1 |
- |
|
| Goel David E. |
10% Owner |
– – • |
2022-12-05 |
4 |
B |
$12.00 |
$15,000,000 |
I/I |
1,250,000 |
5,362,870 |
1.5 |
- |
|
| Johnson David Michael |
Director |
– • – |
2022-12-01 |
4 |
B |
$12.37 |
$123,700 |
I/I |
10,000 |
15,000 |
2.1 |
- |
|
| Feder Julie B |
Chief Financial Officer |
• – – |
2022-10-31 |
4 |
AS |
$12.45 |
$25,090 |
D/D |
(2,015) |
24,235 |
|
- |
|
| Rich Cadmus |
See Remarks |
• – – |
2022-10-31 |
4 |
AS |
$12.45 |
$20,813 |
D/D |
(1,672) |
24,578 |
|
- |
|
| De Los Pinos Elisabet |
See Remarks |
• • – |
2022-10-31 |
4 |
AS |
$12.46 |
$71,082 |
D/D |
(5,706) |
68,651 |
|
- |
|
| De Rosch Mark |
Chief Operating Officer |
• – – |
2022-10-31 |
4 |
AS |
$12.46 |
$13,890 |
D/D |
(1,115) |
16,385 |
|
- |
|
| Medicxi Growth I Gp Ltd |
10% Owner |
– – • |
2021-11-02 |
4 |
B |
$14.00 |
$9,940,000 |
I/I |
710,000 |
70,540 |
1.5 |
- |
|
| Medicxi Growth I Gp Ltd |
10% Owner |
– – • |
2021-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
2,329,892 |
54,065 |
|
- |
|
| Goel David E. |
10% Owner |
– – • |
2021-11-02 |
4 |
B |
$14.00 |
$24,990,000 |
I/I |
1,785,000 |
4,112,870 |
1.5 |
- |
|
| Goel David E. |
10% Owner |
– – • |
2021-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
2,327,870 |
2,327,870 |
|
- |
|
| Johnson David Michael |
Director |
– • – |
2021-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
139,672 |
139,672 |
|
- |
|
| De Los Pinos Elisabet |
See Remarks |
• • – |
2021-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
4,552 |
131,412 |
|
- |
|
| Rich Cadmus |
See Remarks |
• – – |
2021-10-28 |
4 |
A |
$0.00 |
$0 |
D/D |
26,250 |
26,250 |
|
- |
|
| De Los Pinos Elisabet |
See Remarks |
• • – |
2021-10-28 |
4 |
A |
$0.00 |
$0 |
D/D |
74,357 |
74,357 |
|
- |
|
| De Rosch Mark |
Chief Operating Officer |
• – – |
2021-10-28 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
17,500 |
|
- |
|
| Primiano Christopher Brett |
Chief Business Officer |
• – – |
2021-10-28 |
4 |
A |
$0.00 |
$0 |
D/D |
8,750 |
8,750 |
|
- |
|
| Feder Julie B |
Chief Financial Officer |
• – – |
2021-10-28 |
4 |
A |
$0.00 |
$0 |
D/D |
26,250 |
26,250 |
|
- |
|
| De Los Pinos Elisabet |
Chief Executive OfficerOfficer |
• • – |
2021-10-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
126,860 |
|
- |
|
45 Records found
|
|
Page 2 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
